Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23402376 | 0.94 | ALDH1A1 (0.37) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL23399295 | 0.86 | — | — | |
| SCHEMBL8305875 | 0.81 | KDM4E (0.33) | KDM4E | |
| SCHEMBL292558 | 0.78 | NPC1 (0.40) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL292557 | 0.77 | NPC1 (0.39) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL9020965 | 0.77 | NPC1 (0.42) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL17943853 | 0.77 | NPC1 (0.42) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL474839 | 0.77 | TLR8 (0.44) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL9020584 | 0.77 | NPC1 (0.42) | NPC1RAB9AHTTLMNAAPOBEC3A | |
| SCHEMBL9729198 | 0.76 | KDR (0.46) | NPC1RAB9AHTTLMNAAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1056139-C | Preparation of 1-(HET)ary1-3-hydroxypyrazoles | BASF AG (DE) | 2000-09-06 | — | — | CN | claimed |
| CN-1112552-A | Preparation of 1-(HET)ary1-3-hydroxypyrazoles | BASF AG (DE) | 1995-11-29 | — | — | CN | claimed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| CN-1056139-C | Preparation of 1-(HET)ary1-3-hydroxypyrazoles | BASF AG (DE) | 2000-09-06 | — | — | CN | disclosed |
| US-5559244-A | Preparation of 1-(het) aryl-3-hydroxypyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 1996-09-24 | — | — | US | disclosed |
| CN-1112552-A | Preparation of 1-(HET)ary1-3-hydroxypyrazoles | BASF AG (DE) | 1995-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | HTR4, HTR2B, HTR5A | NPC1 3349/4885RAB9A 3690/4885HTT 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.